adaptimmune limited
adaptimmune limited Company Information
Company Number
06456741
Website
www.adaptimmune.comRegistered Address
60 jubilee avenue, milton park, abingdon, oxfordshire, OX14 4RX
Industry
Other research and experimental development on natural sciences and engineering
Telephone
01235430000
Next Accounts Due
September 2025
Group Structure
View All
Shareholders
adaptimmune therapeutics plc 100%
adaptimmune limited Estimated Valuation
Pomanda estimates the enterprise value of ADAPTIMMUNE LIMITED at £124.2m based on a Turnover of £49.4m and 2.51x industry multiple (adjusted for size and gross margin).
adaptimmune limited Estimated Valuation
Pomanda estimates the enterprise value of ADAPTIMMUNE LIMITED at £0 based on an EBITDA of £-84.5m and a 11.09x industry multiple (adjusted for size and gross margin).
adaptimmune limited Estimated Valuation
Pomanda estimates the enterprise value of ADAPTIMMUNE LIMITED at £0 based on Net Assets of £-615.4m and 2.55x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Adaptimmune Limited Overview
Adaptimmune Limited is a live company located in abingdon, OX14 4RX with a Companies House number of 06456741. It operates in the other research and experimental development on natural sciences and engineering sector, SIC Code 72190. Founded in December 2007, it's largest shareholder is adaptimmune therapeutics plc with a 100% stake. Adaptimmune Limited is a established, large sized company, Pomanda has estimated its turnover at £49.4m with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Adaptimmune Limited Health Check
Pomanda's financial health check has awarded Adaptimmune Limited a 4 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 4 areas for improvement. Company Health Check FAQs
6 Strong
1 Regular
4 Weak
Size
annual sales of £49.4m, make it larger than the average company (£4.5m)
£49.4m - Adaptimmune Limited
£4.5m - Industry AVG
Growth
3 year (CAGR) sales growth of 152%, show it is growing at a faster rate (6.5%)
152% - Adaptimmune Limited
6.5% - Industry AVG
Production
with a gross margin of 44.2%, this company has a comparable cost of product (44.2%)
44.2% - Adaptimmune Limited
44.2% - Industry AVG
Profitability
an operating margin of -178.5% make it less profitable than the average company (3.2%)
-178.5% - Adaptimmune Limited
3.2% - Industry AVG
Employees
with 233 employees, this is above the industry average (49)
233 - Adaptimmune Limited
49 - Industry AVG
Pay Structure
on an average salary of £106.6k, the company has a higher pay structure (£61.8k)
£106.6k - Adaptimmune Limited
£61.8k - Industry AVG
Efficiency
resulting in sales per employee of £212.2k, this is more efficient (£108.9k)
£212.2k - Adaptimmune Limited
£108.9k - Industry AVG
Debtor Days
it gets paid by customers after 4 days, this is earlier than average (55 days)
4 days - Adaptimmune Limited
55 days - Industry AVG
Creditor Days
its suppliers are paid after 59 days, this is slower than average (46 days)
59 days - Adaptimmune Limited
46 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Adaptimmune Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 2 weeks, this is less cash available to meet short term requirements (36 weeks)
2 weeks - Adaptimmune Limited
36 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 641.8%, this is a higher level of debt than the average (42.2%)
641.8% - Adaptimmune Limited
42.2% - Industry AVG
ADAPTIMMUNE LIMITED financials
Adaptimmune Limited's latest turnover from December 2023 is £49.4 million and the company has net assets of -£615.4 million. According to their latest financial statements, Adaptimmune Limited has 233 employees and maintains cash reserves of £32.3 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 49,448,000 | 22,152,000 | 4,440,000 | 3,073,000 | 879,000 | 45,064,000 | 28,791,000 | 10,918,000 | 5,499,000 | 6,818,000 | 355,184 | 0 | |||
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | |||||||||||||||
| Gross Profit | |||||||||||||||
| Admin Expenses | |||||||||||||||
| Operating Profit | -88,247,000 | -154,295,000 | -132,736,000 | -116,919,000 | -114,606,000 | -76,323,000 | -62,395,000 | -51,315,000 | -15,053,000 | -12,787,000 | -8,437,607 | -6,151,094 | |||
| Interest Payable | 693,000 | 44,563,000 | 35,556,000 | 25,445,000 | 18,933,000 | 3,845,000 | 4,592,000 | 2,967,000 | 1,357,000 | 347,000 | 4,454 | 3,947 | |||
| Interest Receivable | 26,734,000 | 79,000 | 2,000 | 12,466,000 | 8,917,000 | 833,000 | 1,712,000 | 824,000 | 321,000 | 320,000 | 1,520 | 9,298 | |||
| Pre-Tax Profit | -62,206,000 | -198,779,000 | -168,290,000 | -129,898,000 | -124,622,000 | -82,910,000 | -61,187,000 | -51,952,000 | -7,613,000 | -11,226,000 | -8,440,541 | -6,145,743 | |||
| Tax | 12,172,000 | 24,209,000 | 28,259,000 | 21,377,000 | 14,591,000 | 12,520,000 | 7,420,000 | 4,289,000 | 1,196,000 | 1,497,000 | 982,427 | 578,016 | |||
| Profit After Tax | -50,034,000 | -174,570,000 | -140,031,000 | -108,521,000 | -110,031,000 | -70,390,000 | -53,767,000 | -47,663,000 | -6,417,000 | -9,729,000 | -7,458,114 | -5,567,727 | |||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Retained Profit | -50,034,000 | -174,570,000 | -140,031,000 | -108,521,000 | -110,031,000 | -70,390,000 | -53,767,000 | -47,663,000 | -6,417,000 | -9,729,000 | -7,458,114 | -5,567,727 | |||
| Employee Costs | 24,833,000 | 29,829,000 | 25,961,000 | 22,226,000 | 18,499,000 | 20,934,000 | 14,510,000 | 12,635,000 | 3,688,000 | 4,878,000 | 2,133,701 | 1,312,462 | |||
| Number Of Employees | 233 | 298 | 252 | 228 | 243 | 252 | 221 | 192 | 127 | 62 | 31 | 19 | |||
| EBITDA* | -84,475,000 | -150,445,000 | -129,003,000 | -113,476,000 | -110,535,000 | -72,292,000 | -59,099,000 | -49,208,000 | -14,319,000 | -12,345,000 | -8,290,461 | -6,120,688 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 22,096,000 | 35,604,000 | 22,953,000 | 33,688,000 | 41,553,000 | 35,103,000 | 34,186,000 | 16,820,000 | 13,353,000 | 3,115,000 | 840,102 | 136,568 | 58,016 | 35 | 1,197 |
| Intangible Assets | 13,528,000 | 4,601,000 | 9,290,000 | 8,933,000 | 8,319,000 | 5,130,000 | 5,163,000 | 4,650,000 | 1,868,000 | 113,000 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 111,000 | 0 | 0 | 0 | 1,907,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 63 | 63 | 0 |
| Debtors (Due After 1 year) | 0 | 1,339,000 | 477,000 | 16,345,000 | 16,879,000 | 15,170,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 35,735,000 | 40,205,000 | 32,243,000 | 42,621,000 | 47,658,000 | 40,233,000 | 39,349,000 | 21,470,000 | 15,221,000 | 3,228,000 | 840,102 | 136,568 | 58,079 | 98 | 1,197 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 649,000 | 6,143,000 | 557,000 | 102,000 | 0 | 151,000 | 152,000 | 1,200,000 | 3,002,000 | 2,000 | 15,559 | 1,105 | 524,192 | 234,463 | 310,522 |
| Group Debtors | 2,882,000 | 1,128,000 | 2,069,000 | 1,346,000 | 959,000 | 1,950,000 | 586,000 | 767,000 | 2,973,000 | 1,318,000 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 41,225,000 | 7,777,000 | 8,190,000 | 4,038,000 | 6,792,000 | 5,534,000 | 4,387,000 | 6,327,000 | 4,596,000 | 3,888,000 | 608,985 | 312,593 | 0 | 0 | 0 |
| Cash | 32,344,000 | 54,612,000 | 58,843,000 | 18,761,000 | 18,954,000 | 26,496,000 | 57,558,000 | 144,501,000 | 129,884,000 | 145,453,000 | 30,105,084 | 162,729 | 1,828,544 | 753,714 | 897,408 |
| misc current assets | 742,000 | 1,106,000 | 2,176,000 | 18,396,000 | 823,000 | 13,398,000 | 102,918,000 | 6,014,000 | 39,855,000 | 37,753,000 | 1,027,176 | 578,460 | 0 | 0 | 0 |
| total current assets | 77,842,000 | 95,687,000 | 94,634,000 | 42,643,000 | 42,122,000 | 47,529,000 | 165,601,000 | 158,809,000 | 180,310,000 | 188,414,000 | 31,756,804 | 1,054,887 | 2,352,736 | 988,177 | 1,207,930 |
| total assets | 113,577,000 | 135,892,000 | 126,877,000 | 85,264,000 | 89,780,000 | 87,762,000 | 204,950,000 | 180,279,000 | 195,531,000 | 191,642,000 | 32,596,906 | 1,191,455 | 2,410,815 | 988,275 | 1,209,127 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,010,591 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 4,511,000 | 2,880,000 | 4,800,000 | 3,660,000 | 4,000,000 | 1,622,000 | 5,337,000 | 6,047,000 | 5,043,000 | 1,071,000 | 594,485 | 1,260,330 | 2,564,274 | 378,207 | 401,432 |
| Group/Directors Accounts | 560,009,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 1,392,000 | 1,162,000 | 1,156,000 | 1,337,000 | 1,259,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 35,706,000 | 556,874,000 | 376,678,000 | 42,758,000 | 36,359,000 | 22,644,000 | 50,717,000 | 17,445,000 | 125,457,000 | 128,497,000 | 30,587,590 | 337,923 | 0 | 0 | 0 |
| total current liabilities | 601,618,000 | 560,916,000 | 382,634,000 | 47,755,000 | 41,618,000 | 24,266,000 | 56,054,000 | 23,492,000 | 130,500,000 | 129,568,000 | 31,182,075 | 2,608,844 | 2,564,274 | 378,207 | 401,432 |
| loans | 0 | 20,680,000 | 22,656,000 | 15,760,000 | 17,770,000 | 172,629,000 | 199,711,000 | 135,146,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 9,701,000 | 10,340,000 | 11,328,000 | 7,880,000 | 8,885,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 132,936,000 | 131,302,000 | 0 | 0 | 255,000 | 243,000 | 20,245,000 | 17,973,000 | 9,100,000 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 117,637,000 | 529,000 | 287,000 | 282,280,000 | 224,988,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 72,342,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 127,338,000 | 143,805,000 | 142,917,000 | 326,331,000 | 233,873,000 | 172,884,000 | 199,954,000 | 155,391,000 | 17,973,000 | 9,100,000 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 728,956,000 | 704,721,000 | 525,551,000 | 374,086,000 | 275,491,000 | 197,150,000 | 256,008,000 | 178,883,000 | 148,473,000 | 138,668,000 | 31,182,075 | 2,608,844 | 2,564,274 | 378,207 | 401,432 |
| net assets | -615,379,000 | -568,829,000 | -398,674,000 | -288,822,000 | -185,711,000 | -109,388,000 | -51,058,000 | 1,396,000 | 47,058,000 | 52,974,000 | 1,414,831 | -1,417,389 | -153,459 | 610,068 | 807,695 |
| total shareholders funds | -615,379,000 | -568,829,000 | -398,674,000 | -288,822,000 | -185,711,000 | -109,388,000 | -51,058,000 | 1,396,000 | 47,058,000 | 52,974,000 | 1,414,831 | -1,417,389 | -153,459 | 610,068 | 807,695 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | -88,247,000 | -154,295,000 | -132,736,000 | -116,919,000 | -114,606,000 | -76,323,000 | -62,395,000 | -51,315,000 | -15,053,000 | -12,787,000 | -8,437,607 | -6,151,094 | |||
| Depreciation | 3,753,000 | 3,772,000 | 3,666,000 | 3,340,000 | 3,678,000 | 3,729,000 | 3,020,000 | 2,107,000 | 734,000 | 442,000 | 147,146 | 30,406 | 1,019 | 1,162 | 1,161 |
| Amortisation | 19,000 | 78,000 | 67,000 | 103,000 | 393,000 | 302,000 | 276,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 12,172,000 | 24,209,000 | 28,259,000 | 21,377,000 | 14,591,000 | 12,520,000 | 7,420,000 | 4,289,000 | 1,196,000 | 1,497,000 | 982,427 | 578,016 | |||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 28,369,000 | 5,094,000 | -10,538,000 | -2,799,000 | 1,825,000 | 17,680,000 | -3,169,000 | -2,277,000 | 9,946,456 | 4,583,456 | 310,846 | -210,494 | 289,729 | -76,059 | 310,522 |
| Creditors | 1,631,000 | -1,920,000 | 1,140,000 | -340,000 | 2,378,000 | -3,715,000 | -710,000 | 1,004,000 | 4,448,515 | 476,515 | -665,845 | -1,303,944 | 2,186,067 | -23,225 | 401,432 |
| Accruals and Deferred Income | -654,104,000 | 181,830,000 | 465,222,000 | 6,399,000 | 13,460,000 | -28,061,000 | 13,270,000 | -105,740,000 | 112,842,410 | 107,009,410 | 30,249,667 | 337,923 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | -72,342,000 | 72,342,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | -753,145,000 | 48,580,000 | 303,814,000 | -10,899,000 | -81,931,000 | -109,228,000 | -35,950,000 | -147,378,000 | 94,221,469 | 92,054,469 | 21,964,942 | -6,298,199 | |||
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | 111,000 | 0 | 0 | -1,907,000 | 1,907,000 | 0 | 0 | 0 | 0 | 0 | 0 | -63 | 0 | 63 | 0 |
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 560,009,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | -20,680,000 | -1,976,000 | 6,896,000 | -2,010,000 | -154,859,000 | -27,082,000 | 64,565,000 | 135,146,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | -409,000 | -982,000 | 3,267,000 | -927,000 | 10,144,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 117,108,000 | 242,000 | -281,993,000 | 57,292,000 | 224,988,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||||||||
| interest | 26,041,000 | -44,484,000 | -35,554,000 | -12,979,000 | -10,016,000 | -3,012,000 | -2,880,000 | -2,143,000 | -1,036,000 | -27,000 | -2,934 | 5,351 | |||
| cash flow from financing | 685,553,000 | -42,785,000 | -277,205,000 | 46,786,000 | 103,965,000 | -18,034,000 | 62,998,000 | 135,004,000 | 51,024,169 | 61,261,169 | 10,287,400 | 4,309,148 | |||
| cash and cash equivalents | |||||||||||||||
| cash | -22,268,000 | -4,231,000 | 40,082,000 | -193,000 | -7,542,000 | -31,062,000 | -86,943,000 | 14,617,000 | 99,778,916 | 115,347,916 | 29,942,355 | -1,665,815 | 1,074,830 | -143,694 | 897,408 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1,010,591 | 1,010,591 | 0 | 0 | 0 |
| change in cash | -22,268,000 | -4,231,000 | 40,082,000 | -193,000 | -7,542,000 | -31,062,000 | -86,943,000 | 14,617,000 | 99,778,916 | 115,347,916 | 30,952,946 | -2,676,406 | 1,074,830 | -143,694 | 897,408 |
adaptimmune limited Credit Report and Business Information
Adaptimmune Limited Competitor Analysis
Perform a competitor analysis for adaptimmune limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other large companies, companies in OX14 area or any other competitors across 12 key performance metrics.
adaptimmune limited Ownership
ADAPTIMMUNE LIMITED group structure
Adaptimmune Limited has no subsidiary companies.
adaptimmune limited directors
Adaptimmune Limited currently has 4 directors. The longest serving directors include Mr Adrian Rawcliffe (Jan 2017) and Dr Helen Tayton-Martin (Jan 2017).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Adrian Rawcliffe | England | 52 years | Jan 2017 | - | Director |
| Dr Helen Tayton-Martin | United Kingdom | 57 years | Jan 2017 | - | Director |
| Mrs Margaret Henry | United Kingdom | 56 years | Sep 2019 | - | Director |
| Mr Gavin Wood | United Kingdom | 54 years | Apr 2020 | - | Director |
P&L
December 2023turnover
49.4m
+123%
operating profit
-88.2m
-43%
gross margin
44.3%
-5.42%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
-615.4m
+0.08%
total assets
113.6m
-0.16%
cash
32.3m
-0.41%
net assets
Total assets minus all liabilities
adaptimmune limited company details
company number
06456741
Type
Private limited with Share Capital
industry
72190 - Other research and experimental development on natural sciences and engineering
incorporation date
December 2007
age
17
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
December 2023
previous names
N/A
accountant
-
auditor
KPMG LLP
address
60 jubilee avenue, milton park, abingdon, oxfordshire, OX14 4RX
Bank
-
Legal Advisor
-
adaptimmune limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 6 charges/mortgages relating to adaptimmune limited. Currently there are 4 open charges and 2 have been satisfied in the past.
adaptimmune limited Companies House Filings - See Documents
| date | description | view/download |
|---|
